Pernix Therapeutics to Acquire U.S Rights to Treximet and Summer Infant Beats on Revenues and Gets Upgrade from Roth Capital

Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) shares hit a one year high after the company announced it would acquire the U.S rights to Treximet in an agreement with GlaxoSmithKline. Treximet is used for the acute treatment of migraine attacks with or without aura in adults. The company expects the acquisition to close no later than Aug. 1st. Pernix also revealed that it anticipates pro forma total revenue for the full year 2015 to exceed $230 million and sees EBTIDA margin greater than 40%. Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, develops, manufactures,